Ticagrelor Tablet
Product Images NDC 50228-521

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 50228-521). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Ticagrelor Tablets 1)

FDA Label Image

9 (Ticagrelor Tablets 10)

This text presents a list of interactions between Ticagrelor and various drugs. It includes information on dose adjustments and recommendations for the interacting drugs such as Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine. It also mentions monitoring of Digoxin levels when making changes in Ticagrelor therapy.*

FDA Label Image

10 (Ticagrelor Tablets 11)

FDA Label Image

11 (Ticagrelor Tablets 12)

FDA Label Image

12 (Ticagrelor Tablets 13)

This information shows the results of ASADose comparing Ticagrelor and Clopidogrel across different regions and doses. Ticagrelor appears to be better than Clopidogrel according to the data provided, with specific data points for different regions and dose ranges given in the table. The table includes HR values with 95% Confidence Intervals for the comparison between Ticagrelor and Clopidogrel in the US and Non-US regions.*

FDA Label Image

13 (Ticagrelor Tablets 14)

FDA Label Image

14 (Ticagrelor Tablets 15)

FDA Label Image

15 (Ticagrelor Tablets 16)

FDA Label Image

16 (Ticagrelor Tablets 17)

FDA Label Image

17 (Ticagrelor Tablets 18)

FDA Label Image

18 (Ticagrelor Tablets 19)

This text seems to be a detailed analysis of patient characteristics, including demographics, medical history, and treatment details. The data appears to be organized in sections covering different aspects such as patient profiles, geographic distribution, medical conditions like diabetes and hypertension, and prior treatments like ASA and statin therapy. Additionally, the text contains information about the distribution of patients receiving different medications, including Ticagrelor and Placebo, along with details on dosage and percentages. Finally, the text includes a section on Heart Rate at 95% confidence intervals and various numerical values related to it. This data appears to be from a clinical trial or medical study.*

FDA Label Image

2 (Ticagrelor Tablets 2)

FDA Label Image

3 (Ticagrelor Tablets 3)

FDA Label Image

4 (Ticagrelor Tablets 4)

FDA Label Image

Abc (Ticagrelor Tablets 5)

FDA Label Image

5 (Ticagrelor Tablets 6)

FDA Label Image

Ticagrelor-tablets-60mg-1000s (Ticagrelor Tablets 60mg 1000s)

Each tablet contains 60 mg of ticagrelor. The usual adult dosage should be referred to the package insert. It is important to keep all medications out of the reach of children. The tablets should be stored at 25°C (77°F) with excursions allowed to 15° to 30°C (59° to 86°F). This product is manufactured by ScieGen Pharmaceuticals, Inc. in Hauppauge, NY 11788. It is dispensed with a Medication Guide for each patient. Each pack contains 1,000 tablets and is for prescription use only.*

FDA Label Image

Ticagrelor-tablets-60mg-30s (Ticagrelor Tablets 60mg 30s)

Each tablet contains 60 mg of Ticagrelor. Usual adult dosage should be consulted as per the package insert. A warning advises keeping the medication out of children's reach. Store at 25°C (77°F) with excursions permitted between 15° to 30°C (59° to 86°F). The manufacturer is ScieGen Pharmaceuticals, Inc. from Hauppauge, NY 11788. The tablets are dispensed with an accompanying Medication Guide for each patient.*

FDA Label Image

Ticagrelor-tablets-60mg-60s (Ticagrelor Tablets 60mg 60s)

Each tablet contains 60 mg of ticagrelor. The usual adult dosage is specified in the package insert. It is important to keep this medication out of the reach of children. Store at 25°C (77°F) with excursions permitted to 15° to 30°C (59° to 86°F). The Medication Guide can be printed from the provided website. This medication is manufactured by ScieGen Pharmaceuticals, Inc. located in Hauppauge, NY 11788. The NDC number for this medication is 50228-521-60. Remember to dispense the accompanying Medication Guide to each patient.*

FDA Label Image

6 (Ticagrelor Tablets 7)

This description is not-available.*

FDA Label Image

7 (Ticagrelor Tablets 8)

This text provides information on the mean effect and 90% confidence interval along with recommendations for adjusting the dose of Ticagrelor (ARI24910) based on intrinsic factors such as age, gender, ethnicity, severe/mild renal disease, and hepatic impairment. The recommendations indicate when no dose adjustment is required for different population groups. Additionally, the text mentions Ticagrelor administration in patients with moderate to severe hepatic impairment and provides a graph for visual representation.*

FDA Label Image

8 (Ticagrelor Tablets 9)

This text includes information about drug interactions involving Ticagrelor and other medications such as Ketoconazole, Diltiazem, Rifampin, Aspirin, Desmopressin, Heparin, Enoxaparin, Cyclosporine, and Fentanyl. It also specifies the type of inhibitors and inducers involved in the interactions, providing dosages and recommendations. It is likely part of a medical or pharmaceutical document guiding healthcare professionals on the administration of these drugs in combination.*

FDA Label Image

Ticagrelor-tablets-90mg-1000s (Ticagrelor Tablets 90mg 1000s)

This text provides information about ticagrelor tablets, with each tablet containing 90 mg of the medication. The usual adult dosage should be referenced in the package insert. A warning is given to keep all medications out of the reach of children. The storage instructions indicate that the tablets should be kept at 25°C (77°F) with excursions permitted to 15° to 30°C (59° to 86°F). The tablets are manufactured by ScieGen Pharmaceuticals, Inc. It also includes the NDC number for identification. The text further indicates that a medication guide should be dispensed to each patient.*

FDA Label Image

Ticagrelor-tablets-90mg-30s (Ticagrelor Tablets 90mg 30s)

Each tablet contains 90 mg ticagrelor, a medication intended for adults. The usual adult dosage should be referred to within the package insert. It is important to store the medication out of the reach of children at 25°C (77°F) with permissible excursions to 15° to 30°C (59° to 86°F). This product is manufactured by ScieGen Pharmaceuticals, Inc. in Hauppauge, NY. Be sure to dispense the accompanying Medication Guide to each patient.*

FDA Label Image

Ticagrelor-tablets-90mg-60s (Ticagrelor Tablets 90mg 60s)

This text provides information about a medication called ticagrelor, with each tablet containing 90 mg. It mentions the usual adult dosage, storage instructions, and a warning to keep the medication out of reach of children. The medication guide can be printed from a specified website. The tablets are manufactured by ScieGen Pharmaceuticals, Inc.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.